Evaluation of drug interactions in intact hepatocytes: Inhibitors of terfenadine metabolism

Toxicology in Vitro

Volumn 10, Issue 6, 1996, Pages 655-663

  Jurima Romet, M ^a   Huang, H S ^a   Beck, D J ^c   Li, A P ^b,c  

^a Bureau of Drug Research   (Canada)

^b In Vitro Technologies Inc   (United States)

^c St Louis School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYTOCHROME P450 ISOENZYME; ERYTHROMYCIN; ITRACONAZOLE; KETOCONAZOLE; NARINGENIN; TERFENADINE; TROLEANDOMYCIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG INTERACTION; DRUG METABOLISM; DRUG OXIDATION; DRUG TRANSFORMATION; FEMALE; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER CELL; LIVER CELL CULTURE; MALE; NONHUMAN; RAT;

ANIMALIA;

EID: 0030483808     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0887-2333(96)00056-2     Document Type: Article

References (32)

1. Aoyama T., Korzekwa K., Nagata K., Gillette J., Gelboin H. V. and Gonzalez F. J. (1990) Estradiol metabolism by complementary deoxyribonucleic acid-expressed human cytochrome P450s. Endocrinology 126, 3101-3106.
2. Benton R. E., Honig P. K., Zamani K., Cantilena L. R. and Woosley R. L. (1996) Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarizaticn on the electrocardiogram. Clinical Pharmacology and Therapeutics 59, 383-388.
3. Crumb W. J., Wible B., Arnold D. J., Payne J. P. and Brown A. M. (1995) Blockade of multiple human cardiac potassium currents by the antihistamine terfenadine: possible mechanism for terfenadine-associated cardiotoxicity. Molecular Pharmacology 47, 181-190.
4. Dawson J. R., Adams D. J. and Wolf C. R. (1985) Induction of drug metabolizing enzymes in human liver cell line HepG2. FEBS Letters 183, 219-222.
5. Diamond L. and Gelboin H. V. (1969) Alpha-naphthoflavone: an inhibitor of hydrocarbon cytotoxicity and microsomal hydroxylase. Science 166, 1023-1025.
6. Doostdar H., Demoz A., Burke M. D., Melvin W. T. and Grant M. H. (1990) Variation in drug-metabolizing enzyme activities during the growth of human HepG2 hepatoma cells. Xenobiotica 22, 973-982.
7. FDA (1992) Warnings issued on nonsedating antihistamines terfenadine and astemizole. (Abstract). Journal of the American Medical Association 268, 705.
8. Garteiz D. A., Hook R. H., Walker B. J. and Okerholm R. A. (1982) Pharmacokinetics and biotransformation studies of terfenadine in man. Arzneimittel-Forschung/ Drug Research 32, 1185-1190.
9. Grant M. H., Duthie S. J., Gray A. G. and Burke M. D. (1988) Mixed function oxidase and UDP-glucuronyl-transferase activities in the human HepG2 hepatoma cell line. Biochemical Pharmacology 37, 4111-4116.
10. 1 activation in human liver microsomes by naringenin and other flavonoids. Carcinogenesis 11, 2275-2279.
11. Honig P. K., Woosley R. L., Zamani K., Cooner D. P. and Cantilena L. R. (1992) Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clinical Pharmacology and Therapeutics 52, 231-238.
12. Honig P. K., Wortham D. C., Hull R., Zamani K., Smith J. E. and Cantilena L. R. (1993a) Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics. Journal of Clinical Pharmacology 33, 1201-1206.
13. Honig P. K., Wortham D. C., Zamani K., Conner D. P., Mullin J. C. and Cantilena L. R. (1993b) Terfenadine-ketoconazole interaction: pharmacokinetic and electro-cardiographic consequences. Journal of the American Medical Association 269, 1513-1518.
14. Honig P. K., Wortham D. C., Lazarev A. and Cantilena L. R. (1996) Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine. Journal of Clinical Pharmacology 36, 345-351.
15. Jurima-Romet M., Casley W. L., Neu J. M. and Huang H. S. (1995) Induction of CYP3A and associated terfenadine N-dealkylation in rat hepatocytes cocultured with 3T3 cells. Cell Biology and Toxicology 11, 313-327.
16. Jurima-Romet M., Crawford K., Cyr T. and Inaba T. (1994) Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metabolism and Disposition 22, 849-857.
17. Jurima-Romet M., Huang H. S., Paul C. J. and Thomas B. H. (1991) Enalapril cytotoxicity in primary cultures of rat hepatocytes. I. Effects of cytochrome P450 inducers and inhibitors. Toxicology Letters 58, 257-267.
18. Li A. P., Roque M. A., Beck D. J. and Kaminski D. L. (1992) Isolation and culturing of hepatocytes from human livers. Journal of Tissue Culture Methods 14, 139-146.
19. Ling K.-H. J., Leeson G. A., Burmaster S. D., Hook R. H., Reith M. K. and Cheng L. K. (1995) Metabolism of terfenadine associated with CYP3A(4) activity in human hepatic microsomes. Drug Metabolism and Disposition 23, 631-636.
20. Monahan B. P., Ferguson C. L., Killeavy E. S., Lloyd B. K., Troy J. and Cantilena L. R., Jr (1990) Torsades de pointes occurring in association with terfenadine use. Journal of the American Medical Association 264, 2788-2790.
21. Pohjala-Sintonen S., Viitsalo M., Toivonen L. and Neuvonen P. (1993) Torsades de pointes after terfenadine-itraconazole interaction. (Abstract). British Medical Journal 306, 186.
22. + channel cloned from human heart. Molecular Pharmacology 44, 1240-1245.
23. Roe A. L., Snawder J. E., Benson R. W., Roberts D. W. and Casciano D. A. (1993) HepG2 cells: an in vitro model for P450-dependent metabolism of acetaminophen. Biochemical and Biophysical Research Communications 190, 15-19.
24. Rodrigues A. D., Mulford D. J., Lee R. D., Surber B. W., Kukulka M. J., Ferrero J. L., Thomas S. B., Shet M. S. and Estabrook R. W. (1995) In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices. Drug Metabolism and Disposition 23, 765-775.
25. Sassa S., Sugita O., Galbraith R. A. and Kappus A. (1987) Drug metabolism by the human hepatoma cell, HepG2. Biochemical and Biophysical Research Communications 143, 52-57.
26. Schuetz E. G., Schuetz J. D., Strom S. C., Thompson M. T., Fisher R. A., Molowa D. T., Li D. and Guzelian P. S. (1993) Regulation of human liver cytochromes P-450 in family 3A in primary and continuous culture of human hepatocytes. Hepatology 18, 1254-1262.
27. Shwed J. A., Walle U. K. and Walle T. (1992) HepG2 cell line as a human model for sulphate conjugation of drugs. Xenobiotica 22, 973-982.
28. Strom S. C., Monteith D. K., Manoharan K. and Novotny A. (1987) Genotoxicity studies with human hepatocytes. In The Isolated Hepatocyte: Use of Toxicology and Xenobiotic Biotransformations. Edited by E. J. Rauckman and G. M. Padilla. pp. 265-280. Academic Press, Orlando, FL.
29. Von Moltke L. L., Greenblatt D. J., Duan S. X., Harmatz J. S. and Shader R. I. (1994) In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. Journal of Clinical Pharmacology 34, 1222-1227.
30. Waxman D. J., Lapenson D. P., Aoyama T., Gelboin H. V., Gonzalez F. J. and Korzekawa K. (1991) Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Archives of Biochemistry and Biophysics 290, 160-166.
31. Woosley R. L., Chen Y., Freiman J. P. and Gillis R. A. (1993) Mechanism of the cardiotoxic actions of terfenadine. Journal of the American Medical Association 269, 1532-1536.
32. Yun C.-H., Okerholm A. and Guengerich F. P. (1993) Oxidation of the antihistamine drug terfenadine in human liver microsomes. Role of cytochrome P-4503A(4) in N-dealkylation and C-hydroxylation. Drug Metabolism and Disposition 21, 4, 403-409.